Efficacy of Iodine Complex Against COVID-19 Patients

Conditions

Corona Virus Infection, Covid19, SARS-CoV-2

Keywords

SARS-Cov-2, COVID-19, Coronavirus, Iodine Complex

Brief summary

The objective of this study is to measure the effect of Iodine complex in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

Detailed description

The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a close-label and adaptive, multi-centered design with 1:1:1:1 allocation ratio and superiority framework.

Sohaib Ashraf, Shoaib Ashraf, Moneeb Ashraf, Iqra Farooq, Rutaba Akmal et al. (54 authors)

Trials2022-01-192 citations

10.1186/s13063-021-05848-8

A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial.

Ashraf S, Ashraf S, Ashraf M, Imran MA, Kalsoom L, Siddiqui UN, Farooq I, Ghufran M, Khokhar RA, Akram MK, Shahid I, Sohaib Ur Rehman M, Akmal R, Tahir A, Zahid A, Ashraf S, Rafique S, Matti N, Nadeem MF, Humayun A, Malik A, Saboor QA, Ahmad A, Ashraf M, Izhar M.

2021-02-105 citations

10.1186/s13063-021-05081-3

Interventions

DRUGIodine Complex

Iodine Complex capsule (200mg) will be given three times a day

DRUGPlacebo

Empty capsule will be given as placebo

DRUGIdoine Complex

Iodine Complex spray form 2 puffs will be given three times a day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

empty capsule will be given as a placebo

Intervention model description

Randomized, controlled, multi-armed, close-label, interventional study designed

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Positive PCR with mild to moderate disease

Exclusion criteria

* Allergic to iodine * Any co-morbidity other than hypertension and dietetics

Design outcomes

Primary

Measure	Time frame	Description
qRT-PCR	14 days	Time taken for viral load clearance
HRCT chest	14 days	Time taken for radiological improvement

Secondary

Measure	Time frame	Description
Severity of Symptoms	14 days	Time taken for symptomatic response in patients

Countries

Pakistan

Contacts

Primary ContactSohaib Ashraf, MBBS

sohaib-ashraf@outlook.com+923334474523

Backup ContactShoaib Ashraf, PhD

sashraf@mgh.harvard.edu+16177949579

Outcome results

None listed